UroGen Pharma (URGN)
UroGen Pharma on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
5.6M
Short interest
settlement 2026-10-15
4.9
Days to cover
-5.0 days vs prior
75.3%
Short share of volume
2026-11-02
185
Fails to deliver
settlement 2026-10-14
Thu 5 Nov
Next earnings
estimated date
-$3.0M
Insider flow, 90 days
0 buys, 4 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in URGN is 5,607,261 shares, down 640,237 shares over the last month. Over the last 48 readings it ranged from 3,915,278 shares (30 May 2025) to 11,283,704 shares (31 October 2025). At the reported average volume of 1.1M shares a day that is 4.9 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/urgn" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 5,607,261 | -27.8% | 1,136,360 | 4.93 |
| 2026-09-30 | 7,766,918 | +24.3% | 783,547 | 9.91 |
| 2026-09-15 | 6,247,498 | +0.0% | 681,702 | 9.16 |
| 2026-08-31 | 6,245,387 | +22.0% | 919,418 | 6.79 |
| 2026-08-14 | 5,120,407 | +11.6% | 1,066,452 | 4.80 |
| 2026-07-31 | 4,589,109 | -19.3% | 691,634 | 6.64 |
| 2026-07-15 | 5,689,384 | -8.5% | 825,084 | 6.90 |
| 2026-06-30 | 6,218,229 | -5.2% | 660,094 | 9.42 |
| 2026-06-15 | 6,557,146 | -5.3% | 664,053 | 9.87 |
| 2026-05-29 | 6,921,016 | +2.3% | 623,859 | 11.09 |
| 2026-05-15 | 6,764,905 | -6.5% | 1,162,466 | 5.82 |
| 2026-04-30 | 7,236,438 | -7.5% | 814,957 | 8.88 |
| 2026-04-15 | 7,826,923 | -6.3% | 699,218 | 11.19 |
| 2026-03-31 | 8,348,466 | -3.3% | 705,960 | 11.83 |
| 2026-03-13 | 8,629,222 | +7.6% | 1,100,950 | 7.84 |
| 2026-02-27 | 8,018,559 | -14.1% | 739,988 | 10.84 |
| 2026-02-13 | 9,335,645 | -9.3% | 617,235 | 15.12 |
| 2026-01-30 | 10,298,661 | -2.5% | 707,229 | 14.56 |
| 2026-01-15 | 10,568,458 | +10.8% | 727,899 | 14.52 |
| 2025-12-31 | 9,541,727 | +23.3% | 704,774 | 13.54 |
| 2025-12-15 | 7,739,834 | -2.6% | 938,036 | 8.25 |
| 2025-11-28 | 7,950,298 | -11.4% | 1,090,302 | 7.29 |
| 2025-11-14 | 8,976,703 | -20.4% | 1,679,557 | 5.34 |
| 2025-10-31 | 11,283,704 | +1.2% | 831,781 | 13.57 |
| 2025-10-15 | 11,148,494 | +27.9% | 1,120,424 | 9.95 |
| 2025-09-30 | 8,715,101 | +9.7% | 1,190,668 | 7.32 |
| 2025-09-15 | 7,943,465 | +13.2% | 1,348,393 | 5.89 |
| 2025-08-29 | 7,017,727 | +2.2% | 945,191 | 7.42 |
| 2025-08-15 | 6,869,486 | -4.1% | 1,157,653 | 5.93 |
| 2025-07-31 | 7,165,041 | -1.8% | 1,447,384 | 4.95 |
| 2025-07-15 | 7,293,235 | +33.8% | 1,073,969 | 6.79 |
| 2025-06-30 | 5,452,730 | -11.0% | 3,300,211 | 1.65 |
| 2025-06-13 | 6,125,129 | +56.4% | 8,116,663 | 1.00 |
| 2025-05-30 | 3,915,278 | -29.9% | 4,083,500 | 1.00 |
| 2025-05-15 | 5,586,633 | +11.4% | 684,731 | 8.16 |
| 2025-04-30 | 5,015,969 | -0.9% | 786,627 | 6.38 |
| 2025-04-15 | 5,059,468 | -10.5% | 509,295 | 9.93 |
| 2025-03-31 | 5,652,192 | -8.1% | 424,221 | 13.32 |
| 2025-03-14 | 6,150,466 | +0.5% | 413,977 | 14.86 |
| 2025-02-28 | 6,118,208 | -1.2% | 392,738 | 15.58 |
| 2025-02-14 | 6,192,520 | +0.6% | 327,018 | 18.94 |
| 2025-01-31 | 6,158,058 | +2.8% | 249,828 | 24.65 |
| 2025-01-15 | 5,990,595 | +2.8% | 494,848 | 12.11 |
| 2024-12-31 | 5,827,536 | +0.3% | 459,871 | 12.67 |
| 2024-12-13 | 5,813,211 | +0.7% | 343,581 | 16.92 |
| 2024-11-29 | 5,773,140 | -10.4% | 438,292 | 13.17 |
| 2024-11-15 | 6,442,057 | -2.4% | 440,174 | 14.64 |
| 2024-10-31 | 6,599,031 | +1.7% | 614,522 | 10.74 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of URGN volume is 75.3%, down 2.7 points over the last five sessions. Over the last 30 readings it ranged from 24.9% (30 October 2026) to 82.8% (27 October 2026). The latest reading is 14.6 points above the 30-session average of 60.8%, on 1.1M shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 813K | 1.1M | 75.3% | 0 |
| 2026-10-30 | 97K | 391K | 24.9% | 0 |
| 2026-10-29 | 211K | 465K | 45.3% | 0 |
| 2026-10-28 | 271K | 480K | 56.4% | 0 |
| 2026-10-27 | 337K | 407K | 82.8% | 0 |
| 2026-10-26 | 124K | 159K | 78.0% | 0 |
| 2026-10-23 | 130K | 186K | 69.8% | 0 |
| 2026-10-22 | 83K | 169K | 49.2% | 0 |
| 2026-10-21 | 141K | 231K | 61.0% | 0 |
| 2026-10-20 | 121K | 199K | 60.8% | 0 |
| 2026-10-19 | 236K | 469K | 50.4% | 0 |
| 2026-10-16 | 133K | 330K | 40.2% | 0 |
| 2026-10-15 | 115K | 244K | 47.1% | 0 |
| 2026-10-14 | 195K | 519K | 37.6% | 0 |
| 2026-10-13 | 191K | 289K | 66.2% | 1,640 |
| 2026-10-12 | 110K | 203K | 54.2% | 0 |
| 2026-10-09 | 132K | 339K | 38.9% | 1,119 |
| 2026-10-08 | 727K | 1.1M | 69.2% | 32,028 |
| 2026-10-07 | 125K | 173K | 72.0% | 0 |
| 2026-10-06 | 247K | 331K | 74.6% | 0 |
| 2026-10-05 | 334K | 760K | 43.9% | 0 |
| 2026-10-02 | 205K | 274K | 75.0% | 0 |
| 2026-10-01 | 181K | 240K | 75.4% | 106 |
| 2026-09-30 | 115K | 146K | 78.5% | 0 |
| 2026-09-29 | 146K | 192K | 76.3% | 0 |
| 2026-09-28 | 263K | 340K | 77.4% | 0 |
| 2026-09-25 | 118K | 172K | 68.8% | 0 |
| 2026-09-24 | 286K | 446K | 64.0% | 0 |
| 2026-09-23 | 403K | 748K | 53.8% | 511 |
| 2026-09-22 | 68K | 122K | 55.9% | 288 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 14 October 2026, the fails-to-deliver balance in URGN is 185 shares, down 39,799 shares over the last settlement date. Over the last 30 readings it ranged from 15 shares (1 July 2026) to 63,500 shares (6 May 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-14 | 185 | $38.26 | $7K |
| 2026-10-13 | 39,984 | $38.28 | $1.5M |
| 2026-10-08 | 200 | $40.70 | $8K |
| 2026-09-25 | 9,187 | $41.23 | $379K |
| 2026-09-22 | 1,328 | $43.20 | $57K |
| 2026-08-17 | 133 | $48.22 | $6K |
| 2026-08-14 | 214 | $48.12 | $10K |
| 2026-08-12 | 349 | $47.11 | $16K |
| 2026-08-11 | 842 | $46.31 | $39K |
| 2026-08-10 | 912 | $46.96 | $43K |
| 2026-08-07 | 351 | $45.60 | $16K |
| 2026-08-03 | 36 | $38.24 | $1K |
| 2026-07-16 | 109 | $39.80 | $4K |
| 2026-07-14 | 313 | $39.51 | $12K |
| 2026-07-13 | 313 | $38.56 | $12K |
| 2026-07-09 | 1,069 | $38.03 | $41K |
| 2026-07-01 | 15 | $36.80 | $552 |
| 2026-06-30 | 75 | $36.07 | $3K |
| 2026-06-29 | 156 | $34.54 | $5K |
| 2026-06-15 | 73 | $29.72 | $2K |
| 2026-06-12 | 9,583 | $29.50 | $283K |
| 2026-06-02 | 222 | $27.03 | $6K |
| 2026-06-01 | 81 | $28.13 | $2K |
| 2026-05-28 | 56 | $29.33 | $2K |
| 2026-05-13 | 15,622 | $29.80 | $466K |
| 2026-05-06 | 63,500 | $23.83 | $1.5M |
| 2026-05-05 | 22 | $23.29 | $512 |
| 2026-05-04 | 554 | $23.00 | $13K |
| 2026-05-01 | 2,822 | $23.83 | $67K |
| 2026-04-30 | 190 | $23.34 | $4K |
Insider trades
SEC Form 4, newest first. JSONInsiders at URGN reported 4 open-market sells worth $3.0M in the last 90 days and no open-market buys. Latest filing: Degnan Chris (Chief Financial Officer) on 2026-10-08.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-08 | Degnan Chris | Chief Financial Officer | Sell | 2K | $36.69 | $81K | 5K |
| 2026-10-08 | Degnan Chris | Chief Financial Officer | Exercise or conversion | 4K | price not stated in the filing | not stated | 7K |
| 2026-09-08 | Smith Jason Drew | General Counsel | Sell | 2K | $42.54 | $65K | 53K |
| 2026-09-08 | Schoenberg Mark | Chief Medical Officer | Sell | 871 | $42.92 | $37K | 60K |
| 2026-09-07 | Smith Jason Drew | General Counsel | Exercise or conversion | 3K | price not stated in the filing | not stated | 55K |
| 2026-09-07 | Schoenberg Mark | Chief Medical Officer | Exercise or conversion | 2K | price not stated in the filing | not stated | 61K |
| 2026-08-26 | Robinson James A. Jr. | Director | Exercise or conversion | 2K | price not stated in the filing | not stated | 8K |
| 2026-08-20 | Schoenberg Mark | Chief Medical Officer | Sell | 61K | $47.05 | $2.9M | 59K |
| 2026-07-09 | Schoenberg Mark | Chief Medical Officer | Sell | 10K | $40.00 | $400K | 120K |
| 2026-06-22 | Schoenberg Mark | Chief Medical Officer | Sell | 10K | $35.01 | $350K | 130K |
| 2026-06-08 | Schoenberg Mark | Chief Medical Officer | Exercise or conversion | 10K | price not stated in the filing | not stated | 145K |
| 2026-06-08 | Schoenberg Mark | Chief Medical Officer | Sell | 5K | $27.30 | $143K | 140K |
| 2026-05-26 | Robinson James A. Jr. | Director | Exercise or conversion | 2K | price not stated in the filing | not stated | 6K |
| 2026-05-08 | Schoenberg Mark | Chief Medical Officer | Sell | 10K | $30.00 | $300K | 135K |
| 2026-02-03 | Smith Jason Drew | General Counsel | Sell | 3K | $19.69 | $52K | 53K |
| 2026-02-03 | Smith Jason Drew | General Counsel | Sell | 2K | $19.69 | $32K | 51K |
| 2026-02-03 | Smith Jason Drew | General Counsel | Sell | 3K | $19.69 | $63K | 56K |
| 2026-02-03 | Schoenberg Mark | Chief Medical Officer | Sell | 4K | $19.69 | $73K | 145K |
| 2026-02-03 | Schoenberg Mark | Chief Medical Officer | Sell | 2K | $19.69 | $36K | 149K |
| 2026-02-03 | Schoenberg Mark | Chief Medical Officer | Sell | 2K | $19.69 | $36K | 151K |
| 2026-01-31 | Schoenberg Mark | Chief Medical Officer | Exercise or conversion | 7K | price not stated in the filing | not stated | 152K |
| 2026-01-31 | Schoenberg Mark | Chief Medical Officer | Exercise or conversion | 3K | price not stated in the filing | not stated | 146K |
| 2026-01-31 | Schoenberg Mark | Chief Medical Officer | Exercise or conversion | 3K | price not stated in the filing | not stated | 142K |
| 2026-01-31 | Smith Jason Drew | General Counsel | Exercise or conversion | 6K | price not stated in the filing | not stated | 55K |
| 2026-01-31 | Smith Jason Drew | General Counsel | Exercise or conversion | 7K | price not stated in the filing | not stated | 50K |
| 2026-01-31 | Smith Jason Drew | General Counsel | Exercise or conversion | 3K | price not stated in the filing | not stated | 59K |
| 2025-11-26 | Wildman Daniel George | Director | Exercise or conversion | 2K | price not stated in the filing | not stated | 2K |
| 2025-11-26 | WEN LEANA | Director | Exercise or conversion | 2K | price not stated in the filing | not stated | 2K |
| 2025-11-26 | Robinson James A. Jr. | Director | Exercise or conversion | 2K | price not stated in the filing | not stated | 2K |
| 2025-11-26 | BUTITTA CYNTHIA M | Director | Exercise or conversion | 2K | price not stated in the filing | not stated | 2K |
| 2025-11-26 | Holden Stuart | Director | Exercise or conversion | 2K | price not stated in the filing | not stated | 2K |
| 2025-11-19 | Schoenberg Mark | Chief Medical Officer | Sell | 10K | $25.00 | $250K | 139K |
| 2025-10-08 | Degnan Chris | Chief Financial Officer | Sell | 2K | $16.85 | $37K | 2K |
| 2025-10-08 | Degnan Chris | Chief Financial Officer | Exercise or conversion | 4K | price not stated in the filing | not stated | 4K |
| 2025-09-08 | Smith Jason Drew | General Counsel | Sell | 2K | $19.11 | $29K | 43K |
| 2025-09-08 | Schoenberg Mark | Chief Medical Officer | Sell | 871 | $19.11 | $17K | 149K |
| 2025-09-07 | Smith Jason Drew | General Counsel | Exercise or conversion | 3K | price not stated in the filing | not stated | 45K |
| 2025-09-07 | Schoenberg Mark | Chief Medical Officer | Exercise or conversion | 2K | price not stated in the filing | not stated | 150K |
| 2025-08-11 | Schoenberg Mark | Chief Medical Officer | Sell | 10K | $17.69 | $177K | 148K |
| 2025-07-28 | Schoenberg Mark | Chief Medical Officer | Exercise or conversion | 10K | price not stated in the filing | not stated | 163K |
| 2025-07-28 | Schoenberg Mark | Chief Medical Officer | Sell | 5K | $19.14 | $99K | 158K |
| 2025-07-28 | Smith Jason Drew | General Counsel | Exercise or conversion | 17K | price not stated in the filing | not stated | 49K |
| 2025-07-28 | Smith Jason Drew | General Counsel | Sell | 8K | $19.14 | $144K | 41K |
| 2025-06-09 | Schoenberg Mark | Chief Medical Officer | Sell | 5K | $7.37 | $38K | 153K |
| 2025-06-08 | Schoenberg Mark | Chief Medical Officer | Exercise or conversion | 10K | price not stated in the filing | not stated | 159K |
| 2025-02-26 | Robinson James A. Jr. | Director | Exercise or conversion | 2K | price not stated in the filing | not stated | 4K |
| 2025-01-31 | Schoenberg Mark | Chief Medical Officer | Sell | 2K | $11.14 | $21K | 149K |
| 2025-01-31 | Schoenberg Mark | Chief Medical Officer | Exercise or conversion | 3K | price not stated in the filing | not stated | 149K |
| 2025-01-31 | Smith Jason Drew | General Counsel | Exercise or conversion | 6K | price not stated in the filing | not stated | 35K |
| 2025-01-31 | Smith Jason Drew | General Counsel | Sell | 3K | $11.14 | $37K | 30K |
| 2025-01-31 | Smith Jason Drew | General Counsel | Sell | 1K | $11.14 | $14K | 26K |
| 2025-01-31 | Smith Jason Drew | General Counsel | Exercise or conversion | 3K | price not stated in the filing | not stated | 28K |
| 2025-01-31 | Smith Jason Drew | General Counsel | Exercise or conversion | 7K | price not stated in the filing | not stated | 33K |
| 2025-01-31 | Smith Jason Drew | General Counsel | Sell | 3K | $11.14 | $31K | 33K |
| 2025-01-31 | Schoenberg Mark | Chief Medical Officer | Exercise or conversion | 1K | price not stated in the filing | not stated | 146K |
| 2025-01-31 | Schoenberg Mark | Chief Medical Officer | Sell | 759 | $11.14 | $8K | 146K |
| 2025-01-31 | Schoenberg Mark | Chief Medical Officer | Sell | 2K | $11.14 | $21K | 147K |
| 2025-01-31 | Schoenberg Mark | Chief Medical Officer | Exercise or conversion | 3K | price not stated in the filing | not stated | 150K |
| 2024-09-09 | Kim Dong | Chief Financial Officer | Exercise or conversion | 3K | price not stated in the filing | not stated | 38K |
| 2024-09-09 | Smith Jason Drew | General Counsel | Sell | 2K | $13.08 | $20K | 25K |
| 2024-09-09 | Smith Jason Drew | General Counsel | Exercise or conversion | 3K | price not stated in the filing | not stated | 27K |
| 2024-09-09 | Schoenberg Mark | Chief Medical Officer | Sell | 859 | $13.08 | $11K | 145K |
| 2024-09-09 | Schoenberg Mark | Chief Medical Officer | Exercise or conversion | 2K | price not stated in the filing | not stated | 146K |
| 2024-06-10 | Schoenberg Mark | Chief Medical Officer | Exercise or conversion | 10K | price not stated in the filing | not stated | 149K |
| 2024-06-10 | Schoenberg Mark | Chief Medical Officer | Sell | 5K | $13.08 | $67K | 144K |
| 2024-03-18 | Schoenberg Mark | Chief Medical Officer | Sell | 12K | $14.05 | $169K | 139K |
| 2024-02-01 | Schoenberg Mark | Chief Medical Officer | Sell | 758 | $15.78 | $12K | 150K |
| 2024-02-01 | Schoenberg Mark | Chief Medical Officer | Sell | 2K | $15.78 | $30K | 151K |
| 2024-02-01 | Schoenberg Mark | Chief Medical Officer | Sell | 1K | $15.78 | $18K | 149K |
| 2024-02-01 | Smith Jason Drew | General Counsel | Sell | 1K | $15.78 | $20K | 20K |
| 2024-02-01 | Smith Jason Drew | General Counsel | Sell | 3K | $15.78 | $53K | 23K |
| 2024-02-01 | Smith Jason Drew | General Counsel | Sell | 417 | $15.78 | $7K | 19K |
| 2024-01-31 | Kim Dong | Chief Financial Officer | Exercise or conversion | 3K | price not stated in the filing | not stated | 27K |
| 2024-01-31 | Schoenberg Mark | Chief Medical Officer | Exercise or conversion | 3K | price not stated in the filing | not stated | 153K |
| 2024-01-31 | Schoenberg Mark | Chief Medical Officer | Exercise or conversion | 2K | price not stated in the filing | not stated | 151K |
| 2024-01-31 | Schoenberg Mark | Chief Medical Officer | Sell | 1K | $15.74 | $18K | 149K |
| 2024-01-31 | Schoenberg Mark | Chief Medical Officer | Sell | 2K | $15.74 | $30K | 151K |
| 2024-01-31 | Schoenberg Mark | Chief Medical Officer | Sell | 758 | $15.74 | $12K | 150K |
| 2024-01-31 | Schoenberg Mark | Chief Medical Officer | Exercise or conversion | 1K | price not stated in the filing | not stated | 151K |
| 2024-01-31 | Smith Jason Drew | General Counsel | Exercise or conversion | 3K | price not stated in the filing | not stated | 21K |
| 2024-01-31 | Smith Jason Drew | General Counsel | Exercise or conversion | 7K | price not stated in the filing | not stated | 27K |
| 2024-01-31 | Smith Jason Drew | General Counsel | Sell | 1K | $15.74 | $20K | 20K |
| 2024-01-31 | Smith Jason Drew | General Counsel | Sell | 3K | $15.74 | $52K | 23K |
| 2024-01-31 | Smith Jason Drew | General Counsel | Sell | 417 | $15.74 | $7K | 19K |
| 2024-01-31 | Smith Jason Drew | General Counsel | Exercise or conversion | 834 | price not stated in the filing | not stated | 19K |
| 2024-01-31 | Kim Dong | Chief Financial Officer | Exercise or conversion | 3K | price not stated in the filing | not stated | 35K |
| 2023-08-31 | Smith Jason Drew | General Counsel | Exercise or conversion | 8K | price not stated in the filing | not stated | 22K |
| 2023-08-31 | Smith Jason Drew | General Counsel | Sell | 4K | $18.01 | $68K | 18K |
| 2023-07-26 | Cohen Fred E | Director | Grant | 69K | $9.54 | $661K | 69K |
| 2023-01-31 | Schoenberg Mark | Chief Medical Officer | Sell | 248 | $10.12 | $3K | 147K |
| 2023-01-31 | Schoenberg Mark | Chief Medical Officer | Exercise or conversion | 500 | price not stated in the filing | not stated | 147K |
| 2023-01-31 | Schoenberg Mark | Chief Medical Officer | Exercise or conversion | 2K | price not stated in the filing | not stated | 149K |
| 2023-01-31 | Schoenberg Mark | Chief Medical Officer | Sell | 991 | $10.12 | $10K | 148K |
| 2023-01-31 | Schoenberg Mark | Chief Medical Officer | Exercise or conversion | 1K | price not stated in the filing | not stated | 149K |
| 2023-01-31 | Schoenberg Mark | Chief Medical Officer | Sell | 661 | $10.12 | $7K | 149K |
| 2023-01-31 | Smith Jason Drew | General Counsel | Exercise or conversion | 833 | price not stated in the filing | not stated | 13K |
| 2023-01-31 | Smith Jason Drew | General Counsel | Exercise or conversion | 3K | price not stated in the filing | not stated | 15K |
| 2023-01-31 | Smith Jason Drew | General Counsel | Sell | 1K | $10.12 | $12K | 14K |
| 2023-01-31 | Smith Jason Drew | General Counsel | Sell | 409 | $10.12 | $4K | 13K |
| 2023-01-31 | Barrett Elizabeth A. | Chief Executive Officer | Exercise or conversion | 5K | price not stated in the filing | not stated | 313K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON10 Form 144 notices on file for URGN worth $4.8M at the prices reported; 4 in the last 90 days worth $3.1M. Latest: Christopher Degnan filed on 2026-10-09 to sell 2,202 shares ($90K) from 2026-10-08.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-10-09 | Christopher DegnanOfficer | 2K | $90K | 0.005% | 2026-10-08 | Oppenheimer & Co. Inc. |
| 2026-09-09 | Jason SmithOfficer | 2K | $67K | 0.003% | 2026-09-08 | Oppenheimer & Co. Inc. |
| 2026-09-09 | Mark SchoenbergOfficer | 871 | $38K | 0.002% | 2026-09-08 | Oppenheimer & Co. Inc. |
| 2026-08-20 | Schoenberg MarkOfficer | 61K | $2.9M | 0.124% | 2026-08-20 | RBC CAPITAL MARKETS LLC |
| 2026-07-09 | Schoenberg MarkOfficer | 10K | $400K | 0.021% | 2026-07-09 | RBC CAPITAL MARKETS LLC |
| 2026-06-22 | Schoenberg MarkOfficer | 10K | $350K | 0.021% | 2026-06-22 | RBC CAPITAL MARKETS LLC |
| 2026-06-09 | Schoenberg MarkOfficer | 5K | $140K | 0.011% | 2026-06-08 | Oppenheimer & Co. Inc. |
| 2026-05-08 | Schoenberg MarkOfficer | 10K | $300K | 0.021% | 2026-05-08 | RBC CAPITAL MARKETS LLC |
| 2026-02-03 | Schoenberg MarkOfficer | 13K | $261K | 0.028% | 2026-02-02 | Oppenheimer & Co. Inc |
| 2025-11-19 | Schoenberg MarkOfficer | 10K | $250K | 0.021% | 2025-11-19 | RBC CAPITAL MARKETS LLC |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON2 holders report 5% or more of URGN in their latest filing, all on Schedule 13G (passive). The largest reported stake is The Toronto-Dominion Bank at 6.7% of the class (3,269,957 shares), filed 2026-08-12 for an event on 2026-06-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-10-27 | 13G/Ano. 1 | BlackRock, Inc.parent holding company | 3.1M | 6.3% | 2026-09-30 |
| 2026-08-12 | 13G/Ano. 1 | The Toronto-Dominion Banknon-US institution | 3.3M | 6.7% | 2026-06-30 |
| 2026-08-12 | 13G/Ano. 1 | TD SECURITIES INC.non-US institution | 101K | 0.2% | 2026-06-30 |
| 2026-05-15 | 13G/Ano. 2 | Senai Asefaw, M.D.individual | 1.7M | 3.5% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 2 | Paradigm BioCapital Advisors LPpartnership | 1.7M | 3.5% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 2 | Paradigm BioCapital Advisors GP LLCother entity | 1.7M | 3.5% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 2 | Paradigm BioCapital International Fund Ltd.corporation | 1.5M | 3.1% | 2026-03-31 |
| 2025-11-14 | 13G/Ano. 2 | Cowen Financial Products LLCother entity | 0 | 0.0% | 2025-09-30 |
13F holders
Tracked managers holding URGN at their latest 13F. JSON8 of the 30 tracked managers held URGN at their latest 13F, $120.0M in total at quarter-end prices. Point72 Asset Management is the largest at $56.1M (0.1% of its portfolio) as of 2026-06-30. Over the prior quarter 4 added shares and 4 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Point72 Asset Management | 2026-06-30 | 1.5M | $56.1M | 0.06% | new |
| D. E. Shaw & Co. | 2026-06-30 | 1.1M | $42.2M | 0.02% | +123K |
| AQR Capital Management | 2026-06-30 | 149K | $5.5M | 0.00% | +5K |
| Two Sigma Investments | 2026-06-30 | 149K | $5.5M | 0.00% | -29K |
| Millennium Management | 2026-06-30 | 107K | $3.9M | 0.00% | -264K |
| ARK Investment Management | 2026-06-30 | 102K | $3.7M | 0.02% | -14K |
| Renaissance Technologies | 2026-06-30 | 70K | $2.6M | 0.00% | new |
| Citadel Advisors | 2026-06-30 | 13K | $478K | 0.00% | -255K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
UroGen Pharma in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows UroGen Pharma (URGN), SEC CIK 1668243, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-14.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-10-09.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-10-27.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-05.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-08.JSON and CSV
- Company record
- EDGAR filing index for CIK 1668243Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of URGN is sold short?
5,607,261 shares were held short at the 2026-10-15 settlement, 4.9 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is URGN's daily short volume?
On 2026-11-02, 813,248 of the 1,079,739 URGN shares reported to FINRA were sold short, 75.3% of the day's reported volume. Short volume is a flow for one day, not a position.
Does URGN have fails to deliver?
The SEC's latest file shows 185 URGN shares failed to deliver at settlement 2026-10-14. Fails are reported per settlement date and published twice a month with a lag.
Are URGN insiders buying or selling?
Insiders at URGN reported 4 open-market sells worth $3.0M in the last 90 days and no open-market buys. Latest filing: Degnan Chris (Chief Financial Officer) on 2026-10-08.
Have URGN insiders filed to sell?
10 Form 144 notices on file for URGN worth $4.8M at the prices reported; 4 in the last 90 days worth $3.1M. Latest: Christopher Degnan filed on 2026-10-09 to sell 2,202 shares ($90K) from 2026-10-08.
Who owns 5% or more of URGN?
2 holders report 5% or more of URGN in their latest filing, all on Schedule 13G (passive). The largest reported stake is The Toronto-Dominion Bank at 6.7% of the class (3,269,957 shares), filed 2026-08-12 for an event on 2026-06-30.
Which tracked 13F managers own URGN?
8 of the 30 tracked 13F managers held URGN shares at their latest filing, $120.0M in all. The largest: Steve Cohen's Point72 Asset Management (1.5M shares, $56.1M), D. E. Shaw & Co. (1.1M shares, $42.2M), Cliff Asness's AQR Capital Management (149K shares, $5.5M), Two Sigma Investments (149K shares, $5.5M), Izzy Englander's Millennium Management (107K shares, $3.9M), Cathie Wood's ARK Investment Management (102K shares, $3.7M). The table above lists all 8.
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.